Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Conditions

Prostatic Neoplasms 1Neuromyelitis Optica 1Myelitis, Transverse 1Myelitis 1Gastrointestinal Stromal Tumors 1Erectile Dysfunction 1

Interventions

eculizumab 3ublituximab 1ravulizumab 1Sugars 1Rituximab 1Plasma Exchange 1OM 89 1N-(4-((5-(hydroxy(phenyl)methyl)pyrrolidin-2-yl)methyl)phenyl)-4-oxo-4,6,7,8-tetrahydropyrrolo(1,2-a)pyrimidine-6-carboxamide 1Mitoxantrone 1LFB-R603 1Interferon beta-1a 1Immunoglobulins, Intravenous 1Blood Specimen Collection 1Adrenal Cortex Hormones 14-Aminopyridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Myelitis, Transverse × 4-Aminopyridine × Clear all
NCT02166346 2018-04-17

Safety and Efficacy of Sustained Release Dalfampridine in Transverse Myelitis (Re-Launch)

Johns Hopkins University

Phase 2 Completed
24 enrolled 10 charts

Myelitis, Myelitis, Transverse, Neuromyelitis Optica

Data powered by HemOnc (CC BY 4.0) Colophon âš¡